https://vid.freedif.org/videos/watch/39a5b4c1-0e1a-4e31-a5ff-7c8f16011209 Novo Nordisk's weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke with patients about their experience on the pill and explains how the drug is facing competition from Eli Lilly's oral weight loss pill. Watch the video to learn more. Produced, Shot, and Edited by: Ryan Baker Reporter: Annika Kim Constantino Animation by: Emily Park Managing Producer: Beatriz Bajuelos Senior Managing Producer: Tala Hadavi Additional Footage: Novo Nordisk, Eli Lilly, Getty Images About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Want to get ahead at work with AI? Sign up for CNBC's new online course, Beyond the Basics: How to Use AI to Supercharge Your Work. Learn advanced AI skills like building custom GPTs and using AI agents to boost your productivity today. Sign up today: https://cnb.cx/4qKBe6H Connect with CNBC News Online Get the latest news: https://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC on Threads: https://cnb.cx/threads Follow CNBC News on X: https://cnb.cx/FollowCNBC Follow CNBC on WhatsApp: https://cnb.cx/WhatsAppCNBC #CNBC Why Novo Nordisk’s Weight Loss Pill Has Taken Off Wed, 08 Apr 2026 12:10:35 GMT https://validator.w3.org/feed/docs/rss2.html PeerTube - https://vid.freedif.org https://vid.freedif.org/client/assets/images/icons/icon-1500x1500.png https://vid.freedif.org/videos/watch/39a5b4c1-0e1a-4e31-a5ff-7c8f16011209 All rights reserved, unless otherwise specified in the terms specified at https://vid.freedif.org/about and potential licenses granted by each content's rightholder.